The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: The care cascade for hepatitis C virus (HCV) infection is impeded by multiple barriers, including suboptimal anti-HCV testing, link to care, and diagnosis. We explored the changes in the care cascade of HCV for the past 20 years and its current status in a large cohort from a tertiary referral center. Methods: We analyzed 1,144,468 patients who had anti-HCV testing between January 2001 and June 2020. Metrics related to the care cascade of HCV infection and the long-term prognosis of patients were explored. Results: The seroprevalence of anti-HCV positivity was 1.8%, with a recent decreasing trend. In all, 69.9% of anti-HCV positive patients performed HCV RNA testing, with a 65.7% positivity. Patients who did not have HCV RNA testing were older and more likely to have a non-hepatocellular carcinoma malignancy, normal alanine aminotransferase level, and good liver function. Linkage times for HCV RNA testing from the anti-HCV positivity and for antiviral treatment from HCV diagnosis decreased, notably after 2015, when highly efficacious oral antiviral treatment was introduced to Korea. The average treatment uptake rate was 35.4%, which increased to 38.9% after 2015. Of the 5,302 patients analyzed for long-term prognosis, the annual incidences of hepatocellular carcinoma were 1.02 or 2.14 per 100 person-years in patients with or without a sustained virological response, respectively. Conclusions: The care cascade of HCV infection has been suboptimal for the past 20 years, despite the recent changes. More effort should be made to increase HCV RNA testing and treatment uptake.
Abstract
Background/Aims: The care cascade for hepatitis C virus (HCV) infection is impeded by multiple barriers, including suboptimal anti-HCV testing, link to care, and diagnosis. We explored the changes in the care cascade of HCV for the past 20 years and its current status in a large cohort from a tertiary referral center. Methods: We analyzed 1,144,468 patients who had anti-HCV testing between January 2001 and June 2020. Metrics related to the care cascade of HCV infection and the long-term prognosis of patients were explored. Results: The seroprevalence of anti-HCV positivity was 1.8%, with a recent decreasing trend. In all, 69.9% of anti-HCV positive patients performed HCV RNA testing, with a 65.7% positivity. Patients who did not have HCV RNA testing were older and more likely to have a non-hepatocellular carcinoma malignancy, normal alanine aminotransferase level, and good liver function. Linkage times for HCV RNA testing from the anti-HCV positivity and for antiviral treatment from HCV diagnosis decreased, notably after 2015, when highly efficacious oral antiviral treatment was introduced to Korea. The average treatment uptake rate was 35.4%, which increased to 38.9% after 2015. Of the 5,302 patients analyzed for long-term prognosis, the annual incidences of hepatocellular carcinoma were 1.02 or 2.14 per 100 person-years in patients with or without a sustained virological response, respectively. Conclusions: The care cascade of HCV infection has been suboptimal for the past 20 years, despite the recent changes. More effort should be made to increase HCV RNA testing and treatment uptake.
참고문헌 (19)
- Polaris Observatory HCV Collaborators, "Global prevalence and genotype distribution of hepatitis C virus infection in 2015 : a modelling study", Lancet Gastroenterol Hepatol, 2, pp.161~176 (2017)
- Jin YJ, "Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection", BMJ Open, 4, pp.e006255~ (2014)
- Ghany MG, "Hepatitis C guidance 2019 update : American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection", Hepatology, 71, pp.686~721 (2020)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C : final update of the series☆", J Hepatol, 73, pp.1170~1218 (2020)
- Omata M, "APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing", Hepatol Int, 10, pp.681~701 (2016)
- World Health Organization (WHO), "Combating hepatitis B and C to reach elimination by 2030", World Health Organization, ~ (2016)
- Maier MM, "Cascade of care for hepatitis C virus infection within the US Veterans Health Administration", Am J Public Health, 106, pp.353~358 (2016)
- Joon Yeul Nam, "Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study", Gut and Liver, 14(2), pp.207~217 (2020), 거트앤리버 소화기연관학회협의회
- Giobbie-Hurder A, "Challenges of guarantee-time bias", J Clin Oncol, 31, pp.2963~2969 (2013)
- Jang ES, "The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015", Hepatol Int, 13, pp.599~608 (2019)
- Yehia BR, "The treatment cascade for chronic hepatitis C virus infection in the United States : a systematic review and meta-analysis", PLoS One, 9, pp.e101554~ (2014)
- Janjua NZ, "The population level cascade of care for hepatitis C in British Columbia, Canada : the BC Hepatitis Testers Cohort(BC-HTC)", EBioMedicine, 12, pp.189~195 (2016)
- Takata K, "The rate of referral of hepatitis virus carriers to hepatologists and the factors contributing to referral", Intern Med, 56, pp.1943~1948 (2017)
- Konerman MA, "Hepatitis C treatment and barriers to eradication", Clin Transl Gastroenterol, 7, pp.e193~ (2016)
- Lee JS, "Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea", J Gastroenterol Hepatol, 36, pp.2479~2485 (2021)
- AASLD-IDSA HCV Guidance Panel, "Hepatitis C guidance 2018 update : AASLD-IDSA recommendations for testing, managing, and treating hepatitis C Virus infection", Clin Infect Dis, 67, pp.1477~1492 (2018)
- van der Meer AJ, "Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis", JAMA, 308, pp.2584~2593 (2012)
- Chung-Feng Huang, "Scaling up the in-hospital hepatitis C virus care cascade in Taiwan", Clinical and Molecular Hepatology, 27(1), pp.136~143 (2021), 대한간학회[DOI]
- Yoshioka N, "Promoting notification and linkage of HBs antigen and anti-HCV antibody-positive patients through hospital alert system", BMC Infect Dis, 17, pp.330~ (2017)